TentoriF., BlayneyM.J., AlbertJ.M., GillespieB.W., KerrP.G., BommerJ.Mortality risk for dialysis patients with different levels of serum calcium, phosphorus and PTH: the Dialysis Outcomes and Practice Patterns Study.Am J Kidney Dis2008; 52: 519–30.
2.
KangS.H., ChoK.H., ParkJ.W., YoonK.W., DoJ.Y.Risk factors for mortality in stable peritoneal dialysis patients.Ren Fail2012; 34: 149–54.
3.
JeanG., TerratJ.C., VanelT., HurotJ.M., LorriauxC., MayorB.High levels of serum fibroblast growth factor (FGF)-23 are associated with increasing mortality in long haemodialysis patients.Nephrol Dial Transplant2009; 24: 2792–6.
4.
StompórT.An overview of the pathophysiology of vascular calcification in chronic kidney disease.Perit Dial Int2007; 27(Suppl 2): S215–22.
5.
SrivathsP.R., GoldsteinS.L., SilversteinD.M., KrishnamurthyR., BrewerE.D.Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients.Pediatr Nephrol2011; 26: 945–51.
6.
OlausonH., QureshiA.R., MiyamotoT., BárányP., HeimbürgerO., LindholmB.Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?Nephrol Dial Transplant2010; 25: 3033–8.
7.
IsakovaT., WahlP., VargasG.S., GutiérrezO.M., SciallaJ., XieH.Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.Kidney Int2011; 79: 1370–8.
8.
GolembiewskaE., Kabat-KoperskaJ., SafranowK., CiechanowskiK.Free water transport is associated with phosphorus control in patients at initiation of peritoneal dialysis.Perit Dial Int2011; 31: 685–7.
BernardoA.P., ContesseS.A., BajoM.A., RodriguesA., Del PesoG., OssorioM.Peritoneal membrane phosphate transport status: a cornerstone in phosphate handling in peritoneal dialysis.Clin J Am Soc Nephrol2011; 6: 591–7.
11.
GutiérrezO.M., MannstadtM., IsakovaT., Rauh-HainJ.A., TamezH., ShahA.Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.N Engl J Med2008; 359: 584–92.
12.
HsuH.J., WuM.S.Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.Am J Med Sci2009; 337: 116–22.
13.
IsakovaT.Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease.Curr Opin Nephrol Hypertens2012; 21: 334–40.
IsakovaT., XieH., Barchi-ChungA., VargasG., SowdenN., HoustonJ.Fibroblast growth factor 23 in patients undergoing peritoneal dialysis.Clin J Am Soc Nephrol2011; 6: 2688–95.
16.
ViaeneL., BammensB., MeijersB.K.I., VanrenterghemY., VanderschuerenD., EvenepoelP.Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients.Nephrol Dial Transplant2012; 27: 2017–22.
